P2Y receptors in GtoPdb v.2021.3

Abstract


P2Y receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on P2Y Receptors [3, 5, 192]) are activated by the endogenous ligands ATP, ADP, uridine triphosphate, uridine diphosphate and UDP-glucose. The relationship of many of the cloned receptors to endogenously expressed receptors is not yet established and so it might be appropriate to use wording such as 'uridine triphosphate-preferring (or ATP-, etc.) P2Y receptor' or 'P2Y1-like', etc., until further, as yet undefined, corroborative criteria can be applied [47, 110, 190, 383, 396]. Clinically used drugs acting on these receptors include the dinucleoside polyphosphate diquafosol, agonist of the P2Y2 receptor subtype, approved in Japan for the management of dry eye disease [241], and the P2Y12 receptor antagonists prasugrel, ticagrelor and cangrelor, all approved as antiplatelet drugs [53, 323].

Published
02-Sep-2021
How to Cite
Abbracchio, M.-P., Boeynaems, J.-M., Boyer, J. L., Burnstock, G., Ceruti, S., Fumagalli, M., Gachet, C., Hills, R., Humphries, R. G., Inoue, K., Jacobson, K. A., Kennedy, C., King, B. F., Lecca, D., Müller, C. E., Miras-Portugal, M. T., Ralevic, V. and Weisman, G. A. (2021) “P2Y receptors in GtoPdb v.2021.3”, IUPHAR/BPS Guide to Pharmacology CITE, 2021(3). doi: 10.2218/gtopdb/F52/2021.3.
Section
Summaries